P/E ratio for Redhill Biopharma (RDHL)

P/E ratio history for Redhill Biopharma from 2013 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Sanofi SNY	16.7	-2,108,170.62%	🇫🇷 France
Merck MRK	40.4	-5,093,076.04%	🇺🇸 USA
GSK plc GSK	12.9	-1,632,559.02%	🇬🇧 UK
Teva Pharmaceutical Industries TEVA	28.3	-3,569,658.64%	🇮🇱 Israel
Taro Pharmaceutical TARO	70.4	-8,883,151.70%	🇮🇱 Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.